Limerick BioPharma
South San Francisco
About Limerick BioPharma
Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients' lives. Their compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug's desired effects. In the monotherapy setting, they are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $47.1M
- Funding stage: Late Stage Venture
- Last round: Debt Financing (Jan 2012)
- Website: limerickbio.com
- Phone: 650-742-0110
Industries & Categories
Biotechnology, Developer Platform, Pharmaceutical
Canonical: https://fsome.com/organization/limerick-biopharma-2436595 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.